• Scientist in a laboratory of Banting 1, office space in the background
    Image
    lock
    Locations / Image
    Scientist in a laboratory of Banting 1, office space in the background

    Scientist in a laboratory of Banting 1, office space in the background.

  • understanding-sma-backgrounder
    PDF
    lock
    Disease Awareness / Fact Sheet
    Spinal Muscular Atrophy

    Understanding spinal muscular atrophy, a rare, neuromuscular genetic disease.

  • the-novartis-aav-platform
    PDF
    lock
    Science & Innovation / Fact Sheet
    The Novartis AAV Platform

    Modified viruses – including adeno-associated viruses – are an efficient way to transport therapeutic genetic material to affected cells.

  • screen-the-unseen-unbranded-newborn-screening-video
    Video
    lock
    Disease Awareness / Video
    Screen the Unseen: Newborn Screening for SMA

    Early signs of spinal muscular atrophy can be subtle, and often go unseen by clinicians – which is why newborn screening is critical to help obtain a prompt diagnosis.

  • novartis-gene-therapies-manufacturing-fact-sheet
    PDF
    lock
    Science & Innovation / Fact Sheet
    The Novartis Gene Therapies Manufacturing Process

    Manufacturing of gene therapy is complex. Novartis has developed a reproducible manufacturing process.

  • novartis-gene-therapies-corporate-fact-sheet
    PDF
    lock
    Corporate Responsibility / Fact Sheet
    About Novartis Gene Therapies

    Novartis Gene Therapies is the world leader in gene therapy, and is reimagining medicine to transform the lives of patients.

  • gtx-north-carolina-facility-overview-video
    Video
    lock
    Science & Innovation / Video
    Gene Therapy Manufacturing in North Carolina

    A new, state-of-the-art gene therapy manufacturing facility in North Carolina, USA

  • gene-therapy-fact-sheet
    PDF
    lock
    Science & Innovation / Fact Sheet
    About Gene Therapy

    Gene therapy – an innovative approach to treating rare, genetic diseases.

  • Aharon (Ronny) Gal, PhD
    Image
    lock
    Leadership / Image
    Aharon (Ronny) Gal, Ph.D.

    Chief Strategy & Growth Officer since July 18, 2022

  • crizanlizumab clinical setting from international managed access program (MAP) infographic thumbnail
    PDF
    lock
    Novartis Access / Infographic
    Crizanlizumab clinical setting from international managed access program (MAP)

    Crizanlizumab clinical setting from international managed access program (MAP) infographic

  • Shreeram Aradhye, Global Drug Development & Chief Medical Officer
    Image
    lock
    Leadership / Image
    Shreeram Aradhye, M.D.

    President, Global Drug Development & Chief Medical Officer since May 16, 2022.

  • Kees Roks, Chief Audit Officer
    Image
    lock
    Leadership / Image
    Kees Roks

    Chief Audit Officer